Monique R. Bernsen

Monique R. Bernsen

Auto-generated profile, based on publicly available information

Monique R. Bernsen

AMIE Core Facility, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2011 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
GBGerben M. van Buul
Gerben M. van Buul
WKWendy L.M. Koevoet
Wendy L.M. Koevoet
NKNicole Kops
Nicole Kops
PBP. Koen Bos
P. Koen Bos
JVJan A.N. Verhaar
Jan A.N. Verhaar
GOGerjo J.V.M. Van Osch
Gerjo J.V.M. Van Osch
Background: Platelet-rich plasma (PRP) has recently been postulated as a treatment for osteoarthritis (OA). Although anabolic effects of PRP on chondrocytes are well documented, no reports are known addressing effects on cartilage degeneration. Since OA is characterized by a catabolic and inflammatory joint environment, the authors investigated whether PRP was able to counteract the effects of such an environment on human osteoarthritic chondrocytes. Hypothesis: Platelet-rich plasma inhibits inflammatory effects of interleukin-1 (IL-1) beta on human osteoarthritic chondrocytes. Study Design: Controlled laboratory study. Methods: Human osteoarthritic chondrocytes were cultured in the presence of IL-1 beta to mimic an osteoarthritic environment. Medium was supplemented with 0%, 1%, or 10% PRP releasate (PRPr, the active releasate of PRP). After 48 hours, gene expression of collagen type II alpha 1 (COL2A1), aggrecan (ACAN), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)4, ADAMTS5, matrix metalloproteinase (MMP)13, and prostaglandin-endoperoxide synthase (PTGS)2 was analyzed. Additionally, glycosaminoglycan (GAG) content, nitric oxide (NO) production, and nuclear factor kappa B (NFκB) activation were studied. Results: Platelet-rich plasma releasate diminished IL-1 beta–induced inhibition of COL2A1 and ACAN gene expression. The PRPr also reduced IL-1 beta–induced increase of ADAMTS4 and PTGS2 gene expression. ADAMTS5 gene expression and GAG content were not influenced by IL-1 beta or additional PRPr. Matrix metalloproteinase 13 gene expression and NO production were upregulated by IL-1 beta but not affected by added PRPr. Finally, PRPr reduced IL-1 beta–induced NFκB activation to control levels containing no IL-1 beta. Conclusion: Platelet-rich plasma releasate diminished multiple inflammatory IL-1 beta–mediated effects on human osteoarthritic chondrocytes, including inhibition of NFκB activation. Clinical Relevance: Platelet-rich plasma releasate counteracts effects of an inflammatory environment on genes regulating matrix degradation and formation in human chondrocytes. Platelet-rich plasma releasate decreases NFκB activation, a major pathway involved in the pathogenesis of OA. These results encourage further study of PRP as a treatment for OA.

1 February 2012 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
EPEsben Plenge
Esben Plenge
DPDirk H. J. Poot
Dirk H. J. Poot
MBMonique Bernsen
Monique Bernsen
GKGyula Kotek
Gyula Kotek
GHGavin Houston
Gavin Houston
EMErik Meijering
Erik Meijering
Improving the resolution in magnetic resonance imaging comes at the cost of either lower signal‐to‐noise ratio, longer acquisition time or both. This study investigates whether so‐called super‐resolution reconstruction methods can increase the resolution in the slice selection direction and, as such, are a viable alternative to direct high‐resolution acquisition in terms of the signal‐to‐noise ratio and acquisition time trade‐offs. The performance of six super‐resolution reconstruction methods and direct high‐resolution acquisitions was compared with respect to these trade‐offs. The methods are based on iterative back‐projection, algebraic reconstruction, and regularized least squares. The algorithms were applied to low‐resolution data sets within which the images were rotated relative to each other. Quantitative experiments involved a computational phantom and a physical phantom containing structures of known dimensions. To visually validate the quantitative evaluations, qualitative experiments were performed, in which images of three different subjects (a phantom, an ex vivo rat knee, and a postmortem mouse) were acquired with different magnetic resonance imaging scanners. The results show that super‐resolution reconstruction can indeed improve the resolution, signal‐to‐noise ratio and acquisition time trade‐offs compared with direct high‐resolution acquisition. Magn Reson Med, 2012.

1 October 2012 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
GBG.M. van Buul
G.M. van Buul
EVE. Villafuertes
E. Villafuertes
PBP.K. Bos
P.K. Bos
JWJ.H. Waarsing
J.H. Waarsing
NKN. Kops
N. Kops
GOG.J.V.M. van Osch
G.J.V.M. van Osch

20 August 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
IVI. Jolanda M. de Vries
I. Jolanda M. de Vries
MBMonique R. Bernsen
Monique R. Bernsen
WLW. Joost Lesterhuis
W. Joost Lesterhuis
NSNicole M. Scharenborg
Nicole M. Scharenborg
SSSimon P. Strijk
Simon P. Strijk
GAGosse J. Adema
Gosse J. Adema
Purpose: Tumor-specific immunomonitoring is essential to evaluate the efficacy of vaccination against cancer. In this study, we investigated the predictive value of the presence or absence of antigen-specific T cells in biopsies from delayed-type hypersensitivity (DTH) sites.Patients and Methods: In our ongoing clinical trials, HLA-A2.1+ melanoma patients were vaccinated with mature dendritic cells (DC) pulsed with melanoma-associated peptides (gp100 and tyrosinase) and keyhole limpet hemocyanin.Results: After intradermal administration of a DTH challenge with gp100- and tyrosinase peptide-loaded DC, essentially all patients showed a positive induration. In clinically responding patients, T cells specific for the antigen preferentially accumulated in the DTH site, as visualized by in situ tetramer staining. Furthermore, significant numbers of functional gp100 and tyrosinase tetramer-positive T cells could be isolated from these DTH biopsies, in accordance with the applied antigen in the DTH challenge. We observed a direct correlation between the presence of DC vaccine-related T cells in the DTH biopsies of stage IV melanoma patients and a positive clinical outcome (P = .0012).Conclusion: These findings demonstrate the potency of this novel approach in the monitoring of vaccination studies in cancer patients.

1 September 2005 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
MDMarcory C. R. F van Dijk
Marcory C. R. F van Dijk
MBMonique R Bernsen
Monique R Bernsen
DRDirk J Ruiter
Dirk J Ruiter
A definite diagnosis cannot be established based on histologic features alone in a large number of Spitz nevi and spitzoid melanomas. In a vast majority of common benign and malignant melanocytic lesions, B-RAF and N-RAS mutations were described, but these were not detected in Spitz nevi. In contrast, H-RAS mutations were frequently encountered in Spitz nevi, but only rarely in melanomas. To date, B-RAF mutation analysis has not been reported in atypical Spitz nevi, and there are only a few reports of it in spitzoid melanomas. We analyzed 96 formalin-fixed, paraffin-embedded spitzoid melanocytic lesions for hotspot mutations in B-RAF, N-RAS, and H-RAS genes to test the assumption whether mutation analysis would assist a more accurate diagnosis of spitzoid melanocytic lesions, which are notoriously difficult to classify. B-RAF or N-RAS mutations were observed in 31 of 36 (86%) spitzoid melanomas, and in 6 of 7 (86%) spitzoid melanoma metastases. In contrast, none of the 14 Spitz nevi and none of the 16 atypical Spitz nevi had mutations in any of the three genes. A B-RAF or N-RAS mutation was found in 8 of 23 (35%) spitzoid lesions suspected for melanoma. H-RAS mutations were detected in 4 of 14 (29%) Spitz nevi, in 3 of 22 (14%) atypical Spitz nevi, in 1 of 15 (7%) spitzoid tumors suspected for melanoma, but in none of the spitzoid melanomas. These results strongly indicate that Spitz nevi and spitzoid melanomas are genetically unrelated entities. Furthermore, we can conclude that mutation analysis may be useful as an additional diagnostic tool to distinguish between benign and malignant spitzoid lesions.

1 May 2008 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
EFEric Farrell
Eric Farrell
PWPiotr Wielopolski
Piotr Wielopolski
PPPredrag Pavljasevic
Predrag Pavljasevic
STSandra van Tiel
Sandra van Tiel
Holger JahrHolger Jahr
Holger Jahr
MBMonique Bernsen
Monique Bernsen